Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
One in two women with advanced ovarian cancer has an HRD-positive tumor
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
BREAKWATER is a Phase 3, randomized, open-label trial testing BRAFTOVI in combination with cetuximab, either alone or with chemotherapy, in patients with untreated BRAF V600E-mutant mCRC
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Subscribe To Our Newsletter & Stay Updated
